Articles related to Ophthalmology

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.

Inconsistent cataract biometry measurements most commonly reflect ocular surface instability, subtle corneal pathology, or suboptimal measurement conditions rather than random error, and a systematic diagnostic approach before repeating scans can meaningfully improve refractive predictability.

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

Primary trabeculectomy reduced the rate of visual field loss by approximately 50% compared with a medications-first approach in newly diagnosed advanced open-angle glaucoma patients across a 5-year randomized trial, though standard quality-of-life instruments failed to detect that clinical benefit.

Erucamide, a naturally occurring lipid molecule, declined as photoreceptors deteriorated in preclinical retinal degeneration models, and restoring it via nanoparticle delivery slowed aspects of tissue breakdown without reversing damage.

Each additional hour of daily digital screen exposure was associated with 21% higher odds of myopia in a 335,524-participant meta-analysis, with the steepest odds increase observed between 1 and 4 hours of daily exposure, though substantial heterogeneity and cross-sectional study designs precluded causal conclusions.